Drug Trial Radar · NCT05535972
To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD
Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
463
Actual
Start
Oct 14, 2022
Primary completion
Sep 25, 2023
Study completion Sep 25, 2023
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Sep 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effectiveness of TRELEGY ELLIPTA on health status in participants with symptomatic COPD. The secondary objective is to evaluate the effectiveness of TRELEGY ELLIPTA on dyspnea and lung function in participants with symptomatic COPD. TRELEGY and ELLIPTA are trademarks of the GlaxoSmithKline group of companies.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
FF/UMEC/VIDrug
FF/UMEC/VI will be administered in a single inhaler Trelegy Ellipta.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in COPD Assessment Test (CAT) Score at Week 12Time frame: Baseline (Day 1, pre-dose) and at Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Dongguan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.